Antibiotics

>

Latest News

Long-Acting Lipoglycopeptides for the Treatment of Severe Infections
Long-Acting Lipoglycopeptides for the Treatment of Severe Infections

September 19th 2024

Long-acting lipoglycopeptides (LGPs) like dalbavancin, oritavancin, and telavancin were developed with extended half-lives, initially targeting acute bacterial skin and skin structure infections (ABSSSIs). However, recent studies have explored their potential in treating other infections, including infective endocarditis (IE), bone and joint infections (BJIs), and bloodstream infections (BSIs), offering an alternative to standard care and outpatient antimicrobial therapy.

By 2050, Global Mortality Associated With Antimicrobial Resistance Could Reach More Than 39 Million People
By 2050, Global Mortality Associated With Antimicrobial Resistance Could Reach More Than 39 Million People

September 18th 2024

A Tale of 2 Settings: How Outpatient Clinics Differ From Institutions in Delivering Stewardship
A Tale of 2 Settings: How Outpatient Clinics Differ From Institutions in Delivering Stewardship

September 11th 2024

Childhood "Antibioticination" Reduces Mortality in Africa
Childhood "Antibioticination" Reduces Mortality in Africa

September 8th 2024

CDC’s Role in Antimicrobial Resistance
CDC’s Role in Antimicrobial Resistance

September 6th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.